Starting from December, Belgium will reimburse Novartis' Zolgensma, which is used to treat spinal muscular atrophy (SMA), The Brussels Times reported on Friday.
"Access to such an important medicine should no longer depend on collection campaigns: the solidarity of the health insurance is needed here," said Federal Health Minister Frank Vandenbroucke.
The contract between Novartis and Belgium states that he drug will be reimbursed for children up to two years old with symptomatic SMA type one or patients with presymptomatic SMA with up to three copies of the SMN2 gene.
In May 2020, the drug had been given approval from both the European Medicines Agency, which issued a favourable opinion on the drug's usefulness and effectiveness, and by the European Comission.
To read more NewsPoints articles, click here.